Temporal trends in the prevalence of autoimmune diseases from 1990 to 2019
- PMID: 37201621
- DOI: 10.1016/j.autrev.2023.103359
Temporal trends in the prevalence of autoimmune diseases from 1990 to 2019
Abstract
Aim: To describe current situation and analyze temporal trends of prevalence for four autoimmune diseases including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), multiple sclerosis (MS) and psoriasis, at the global, continental, and national levels.
Methods: The estimates and 95% uncertainty interval (UI) for age-standardized prevalence rate (ASPR) of RA, IBD, MS and psoriasis were obtained from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019. ASPR of RA, IBD, MS and psoriasis in 2019 was illustrated at the global, continental, and national levels. Joinpoint regression analysis was adopted to analyze the 1990-2019 temporal trends by calculating the annual percentage change (APC) and average APC (AAPC), as well as their 95% confidence interval (CI).
Results: In 2019, the global ASPR of RA, IBD, MS and psoriasis was 224.25 (95% UI: 204.94 to 245.99), 59.25 (95% UI: 52.78 to 66.47), 21.25 (95% UI: 18.52 to 23.91) and 503.62 (95% UI: 486.92 to 519.22), respectively, with ASPRs generally higher in Europe and America than in Africa and Asia. From 1990 to 2019, the global ASPR increased significantly for RA (AAPC = 0.27%, 95% CI: 0.24 to 0.30; P < 0.001) and decreased significantly for IBD (AAPC = -0.73%, 95% CI: -0.76 to -0.70; P < 0.001), MS (AAPC = -0.22%, 95% CI: -0.25 to -0.18; P < 0.001) and psoriasis (AAPC = -0.93%, 95% CI: -0.95 to -0.91; P < 0.001), with the most substantial changes occurring at different continents and periods. The trends of ASPR of these four autoimmune diseases varied significantly across 204 countries and territories.
Conclusions: There is a strong heterogeneity in prevalence (2019), as well as their temporal trends (1990-2019) of autoimmune diseases across the world, highlighting the strong distributive inequities of autoimmune diseases worldwide, which may be instructive for better understanding the epidemiology of these diseases, appropriately allocating the medical resources, as well as making relevant health policies.
Keywords: Autoimmune diseases; Global burden of diseases, injuries, and risk factors study; Joinpoint regression analysis; Prevalence; Trends.
Copyright © 2023. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest None.
Similar articles
-
Age-standardized incidence, prevalence, and mortality rates of autoimmune diseases in women of childbearing age from 1990 to 2019.Autoimmun Rev. 2023 Nov;22(11):103450. doi: 10.1016/j.autrev.2023.103450. Epub 2023 Sep 21. Autoimmun Rev. 2023. PMID: 37741529 Review.
-
Age-standardized incidence, prevalence, and mortality rates of autoimmune diseases in adolescents and young adults (15-39 years): an analysis based on the global burden of disease study 2021.BMC Public Health. 2024 Jul 5;24(1):1800. doi: 10.1186/s12889-024-19290-3. BMC Public Health. 2024. PMID: 38970015 Free PMC article.
-
A global assessment of incidence trends of autoimmune diseases from 1990 to 2019 and predicted changes to 2040.Autoimmun Rev. 2023 Oct;22(10):103407. doi: 10.1016/j.autrev.2023.103407. Epub 2023 Aug 11. Autoimmun Rev. 2023. PMID: 37572826
-
Global, regional, and national burden of stroke from 1990 to 2019: A temporal trend analysis based on the Global Burden of Disease Study 2019.Int J Stroke. 2024 Jul;19(6):686-694. doi: 10.1177/17474930241246955. Epub 2024 Apr 19. Int J Stroke. 2024. PMID: 38567822
-
Global burden and cross-country inequalities in autoimmune diseases from 1990 to 2019.Autoimmun Rev. 2023 Jun;22(6):103326. doi: 10.1016/j.autrev.2023.103326. Epub 2023 Mar 22. Autoimmun Rev. 2023. PMID: 36958621 Review.
Cited by
-
Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules.Antibodies (Basel). 2024 Sep 14;13(3):76. doi: 10.3390/antib13030076. Antibodies (Basel). 2024. PMID: 39311381 Free PMC article. Review.
-
Global, regional and national burden of rheumatoid arthritis from 1990 to 2021, with projections of incidence to 2050: a systematic and comprehensive analysis of the Global Burden of Disease study 2021.Biomark Res. 2025 Mar 24;13(1):47. doi: 10.1186/s40364-025-00760-8. Biomark Res. 2025. PMID: 40128880 Free PMC article.
-
Advances in research on immunocyte iron metabolism, ferroptosis, and their regulatory roles in autoimmune and autoinflammatory diseases.Cell Death Dis. 2024 Jul 4;15(7):481. doi: 10.1038/s41419-024-06807-2. Cell Death Dis. 2024. PMID: 38965216 Free PMC article. Review.
-
Narrowing Down Key Players in Autoimmunity via Single-Cell Multiomics.Eur J Immunol. 2025 Jun;55(6):e51233. doi: 10.1002/eji.202451233. Eur J Immunol. 2025. PMID: 40534591 Free PMC article. Review.
-
The implications of FASN in immune cell biology and related diseases.Cell Death Dis. 2024 Jan 25;15(1):88. doi: 10.1038/s41419-024-06463-6. Cell Death Dis. 2024. PMID: 38272906 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical